BCL9L and colorectal carcinoma: Silencing of BCL9L in HCT-116 TP53-null cells also increased the fraction of surviving cells after 3 days of reversine treatment (Figure 3D) and the number of resistant colonies in HCT-116 TP53-null and CL-40 cells, a CRC cell line harboring the most frequent TP53 mutation in CRC (R248Q, Figure 3E).